What is the latest MONOPHARMA stock price?
The latest stored price for MONOPHARMA is Rs 8.55 as of 2026-09-16.
gimli
MONOPHARMA stock AI analysis
MONOPHARMA Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
MONO PHARMACARE LIMITED is a small-cap stock in Unclassified. This Gimli page shows the latest available MONOPHARMA price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹8.55
1W return
-4.47%
1M return
+4.27%
3M return
-25.33%
6M return
-26.29%
1Y return
-64.96%
Market cap
₹n/a
PE
n/a
PB
n/a
ROE
+10.41%
ROCE
+10.39%
RSI
42.11
Turnover
₹0.00 cr
Why it can matter in screens
- Momentum: MONOPHARMA is below 50DMA, below 200DMA; RSI is 42.11.
- Returns: 1D -4.47%, 1W -4.47%, 1M +4.27%, 3M -25.33%, 1Y -64.96%.
- Trend levels: 52W high ₹25.50, 52W low ₹7.50, off high -66.47%.
- Liquidity: latest turnover is ₹0.00 cr; volume vs 20D is +0.28%.
- Valuation/profitability: PE n/a, PB n/a, ROE +10.41%, ROCE +10.39%.
- Growth: 3Y sales CAGR +65.71%, 3Y profit CAGR +106.64%.
Quick Answers
Is MONOPHARMA above its 50DMA and 200DMA?
MONOPHARMA is below 50DMA, below 200DMA. The latest 50DMA is 9.78 and the latest 200DMA is 15.42.
What are MONOPHARMA PE, ROE and ROCE?
MONOPHARMA has PE n/a, ROE +10.41%, and ROCE +10.39% in Gimli's latest available snapshot.
How has MONOPHARMA performed recently?
MONOPHARMA has returned +4.27% over 1 month, -25.33% over 3 months, and -64.96% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
No recent data available.
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2025-03-31 | 168.34 cr | 8.14 cr | 3.09 cr | 1.75 |
| 2024-03-31 | 122.34 cr | 6.19 cr | 2.44 cr | 1.59 |
| 2023-03-31 | 58.48 cr | 3.10 cr | 1.23 cr | 0.70 |
| 2022-03-31 | 36.98 cr | 1.31 cr | 0.35 cr | 0.20 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2025-03-31 | 110.06 cr | 0.70 cr | 53.56 cr | 31.23 cr |
| 2024-03-31 | 81.11 cr | 0.36 cr | 41.44 cr | 28.13 cr |
| 2023-03-31 | 62.60 cr | 0.42 cr | 40.50 cr | 13.40 cr |
| 2022-03-31 | 14.38 cr | 0.24 cr | 6.44 cr | 4.28 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2025-03-31 | -4.30 cr | -4.53 cr | n/a |
| 2024-03-31 | -8.77 cr | -8.95 cr | n/a |
| 2023-03-31 | -27.75 cr | -28.62 cr | n/a |
| 2022-03-31 | 0.24 cr | 0.23 cr | n/a |
Shareholding Trend
No recent data available.
Industry Peers
No recent data available.
Try these prompts
- Analyze MONO PHARMACARE with valuation, momentum and industry peers
- Compare MONOPHARMA with other Unclassified stocks
- Show small-cap stocks in Unclassified above 50DMA with positive 1M return
- Find Unclassified stocks with improving momentum and reasonable valuation
Related screen ideas
- View Unclassified stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare MONOPHARMA with other Unclassified stocks
Data snapshot: 2026-09-16. Not investment advice.